Search

The ability for vaccines to protect against infectious diseases varies among individuals, but computational models employed to inform policy typically do not account for this variation. Here we examine this issue: we implement a model of vaccine efficacy developed in the context of SARS-CoV-2 in order to evaluate the general implications of modelling correlates of protection on the individual level.

To assess potential benefits and direct healthcare cost savings with expansion of an existing childhood influenza immunisation program, we developed a dynamic transmission model for the state of Western Australia, evaluating increasing coverage in children < 5 years and routinely immunising school-aged children.

Given the beneficial effect of infant rotavirus vaccination efforts should be taken to optimize rotavirus vaccine coverage in those at highest risk

This large population-based study suggests a significant healthcare burden associated with influenza in children with a range of chronic lung diseases

To assess the effects of systemic antibiotics for people with chronic suppurative otitis media.

Participants demonstrated a good understanding of safe prescribing and antimicrobial stewardship

Our population-based cohort study demonstrates that >90% coverage in the first year of a universal 3 + 0 PCV program provided high population-level protection

A biologically active vaccine may produce a low measured vaccine efficacy under a range of epidemiological, vaccine-related and logistical conditions

Pat Tom Holt Snelling PhD, DSc, FRCPath, FRCPI, FAA BMBS DTMH GDipClinEpid PhD FRACP Emeritus Honorary Researcher Head, Infectious Disease

Pat Peter Tom Holt Richmond Snelling PhD, DSc, FRCPath, FRCPI, FAA MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid PhD FRACP Emeritus Honorary Researcher